Rocatinlimab for Eczema
(ROCKET-Horizon Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing a new medication called rocatinlimab to help people with eczema. The goal is to see if it can reduce the redness, itching, and swelling better than other treatments. The study focuses on patients whose eczema is severe and not well-controlled by other treatments.
Will I have to stop taking my current medications?
Yes, you will need to stop taking certain medications before joining the trial. Specifically, you must stop systemic corticosteroids, systemic immunosuppressants, phototherapy, and Janus kinase inhibitors at least 4 weeks before starting. You also need to stop using topical treatments like corticosteroids and immunosuppressants 1 week before starting.
What data supports the effectiveness of the drug Rocatinlimab for eczema?
Is rocatinlimab safe for humans?
Research Team
MD
Principal Investigator
Amgen
Eligibility Criteria
This trial is for adults with moderate-to-severe atopic dermatitis (AD) who haven't responded well to medium or stronger topical corticosteroids, or when such treatments are not advised. Participants must have a significant itch, extensive rash covering at least 10% of their body, and meet specific severity scores on AD scales.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Rocatinlimab or placebo every 4 weeks for 24 weeks with a loading dose at Week 2
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Rocatinlimab
Find a Clinic Near You
Who Is Running the Clinical Trial?
Amgen
Lead Sponsor
Robert A. Bradway
Amgen
Chief Executive Officer since 2012
MBA from Harvard Business School
Paul Burton
Amgen
Chief Medical Officer since 2023
MD from University of London, PhD in Molecular and Cellular Biology from Imperial College London